close
Add to watchlist
NexMed Inc (NEXM) Healthcare, Biotechnology & Drugs
NexMed, Inc., a pharmaceutical and medical technology company, engages in the development of topical pharmaceutical products based on its proprietary NexACT transdermal drug delivery technology. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin and enable concentrations of the active drug to penetrate the desired site of the skin or extremity. The company's products under development include NM100060, a topical nail solution for the treatment of onychomycosis; Vitaros, a topical alprostadil-based cream treatment for patients with erectile dysfunction; and Femprox, an alprostadil-based cream product for the treatment of female sexual arousal disorder. It also focuses on the development of topical treatments for psoriasis. The company has a licensing agreement with Novartis International Pharmaceutical Ltd. for the development, manufacture, and commercialization of NM100060. NexMed, Inc. was founded in 1987 and is based in East Windsor, New Jersey.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.38 |
| Volume | 199483 |
| Volume Avg | 163952 |
| 52 Week High | 12.60 |
| 52 Week Low | 1.80 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -6.21 |
| EPS change Q/Q | -73.29% |
| EPS change Q/Q Yr ago | 1000% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -92.01% |
| REV change Q/Q | 366.67% |
| REV change Q/Q Yr ago | -44% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |